Can You Take Ozempic If You Have Heart Disease? Navigating GLP-1s for Cardiovascular Wellness

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Heart disease is not a contraindication to semaglutide — in several situations it is part of the reason to prescribe it. Ozempic carries an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and Wegovy carries a parallel indication for adults with established cardiovascular disease and either obesity or overweight. The only labeled contraindications are a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and serious hypersensitivity. Whether it fits your particular cardiac history is a decision for your cardiologist and prescriber.

The Cardiovascular Indications Are Real Approvals

Ozempic's cardiovascular indication is specific: reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. It sits alongside its glycemic control indication and a third covering kidney outcomes in type 2 diabetes with chronic kidney disease.

Wegovy's cardiovascular indication covers adults with established cardiovascular disease and either obesity or overweight, in combination with a reduced-calorie diet and increased physical activity. Notably, it does not require diabetes.

These are not off-label extrapolations from weight data. Each is an approved claim supported by a dedicated cardiovascular outcomes trial, which is a materially different level of evidence from an observed association.

What the Outcomes Trial Showed

The trial reported as Study 1 in the Wegovy label randomised 8,801 and 8,803 participants. The primary composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 6.5% on semaglutide versus 8% on placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90).

All-cause death was 4.3% versus 5.2%, hazard ratio 0.81 (0.71 to 0.93). Fatal or non-fatal myocardial infarction was 2.8% versus 3.8%, hazard ratio 0.72 (0.61 to 0.85). Cardiovascular death alone, the first confirmatory secondary endpoint, did not reach the prespecified threshold for superiority.

The label is explicit that an effect on heart failure has not been established. Hospitalization for heart failure or urgent heart failure visits occurred in 1.1% versus 1.4%, but that endpoint was not in the prespecified hierarchy for controlling type-I error.

Heart Rate Rises Slightly — and That Is Expected

In the same trial, mean heart rate increased by 3.8 beats per minute on semaglutide versus 0.7 with placebo at week 104, a difference of 3.1 beats per minute. A small increase in resting heart rate is a recognised class effect of GLP-1 receptor agonists.

Systolic blood pressure moved the other way: a mean reduction of 3.8 mmHg versus 0.5 mmHg with placebo, a difference of 3.3 mmHg from a baseline of 131 mmHg. Mean body weight change was −9.4 kg versus −0.93 kg.

For most people those changes are unremarkable. For someone with a tachyarrhythmia history, or on rate-controlling therapy, they are worth raising explicitly with the cardiologist who manages that condition.

The Warnings That Interact With Cardiac Care

Acute kidney injury due to volume depletion is the one to watch. The Ozempic label directs monitoring of renal function in patients reporting adverse reactions that could lead to volume depletion — that is, nausea, vomiting and diarrhea.

That risk compounds with diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and mineralocorticoid receptor antagonists, all standard in cardiac care. Persistent gastrointestinal symptoms on this combination warrant contacting your prescriber rather than waiting.

Delayed gastric emptying also has a procedural implication. Both labels carry a warning about pulmonary aspiration during general anesthesia or deep sedation in patients receiving GLP-1 receptor agonists, and instruct patients to inform their healthcare providers of any planned surgeries or procedures. Cardiac catheterisation and cardioversion count.

Oral Cardiac Medications and Gastric Emptying

Ozempic section 7.2 notes the potential to affect absorption of concomitant oral medications, reports no clinically relevant effect in clinical pharmacology trials, and advises caution. Wegovy section 7.2 additionally directs prescribers to consider increased clinical or laboratory monitoring for oral medications with a narrow therapeutic index or that require clinical monitoring.

Several cardiac drugs fall into that category. Warfarin is the obvious example — the semaglutide tablet interaction programme found no clinically significant pharmacokinetic difference for S-warfarin or R-warfarin, but international normalised ratio monitoring is a clinical matter rather than a pharmacokinetic one.

Digoxin was also studied without a clinically significant difference. The point is not that interactions are inevitable, but that the Wegovy label asks for active monitoring, and your prescriber decides what that means for your regimen.

Bringing Cardiology and Prescribing Together

Make sure both clinicians know. A cardiologist adjusting rate control or diuretics needs to know you are on a GLP-1 receptor agonist, and a prescriber managing that medication needs to know about volume-sensitive cardiac therapy.

Document the diagnosis precisely. Established cardiovascular disease is what both cardiovascular indications are written around, and having it recorded explicitly rather than implied affects both clinical reasoning and coverage review.

And keep the products straight. Ozempic's cardiovascular indication requires type 2 diabetes; Wegovy's does not. Mounjaro and Zepbound have their own separate indications, and a compounded preparation carries no approved cardiovascular claim of any kind.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is heart disease a reason to avoid semaglutide?

Generally the opposite. Ozempic carries an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and Wegovy carries a parallel indication for adults with established cardiovascular disease and either obesity or overweight. The only labeled contraindications are medullary thyroid carcinoma history, MEN 2, and serious hypersensitivity.

How much does semaglutide reduce cardiovascular risk?

In the trial reported as Study 1 in the Wegovy label, with 8,801 and 8,803 participants, the primary composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 6.5% on semaglutide versus 8% on placebo, hazard ratio 0.80 (95% CI 0.72 to 0.90). All-cause death was 4.3% versus 5.2%, hazard ratio 0.81.

Does it help heart failure?

The Wegovy label states explicitly that an effect on heart failure has not been established. Hospitalization for heart failure or urgent heart failure visits occurred in 1.1% on semaglutide versus 1.4% on placebo in the outcomes trial, but that endpoint was not included in the prespecified testing hierarchy for controlling type-I error, so it cannot support a claim.

Should I worry about the heart rate increase?

A small rise in resting heart rate is a recognised class effect. In the outcomes trial, mean heart rate rose 3.8 beats per minute on semaglutide versus 0.7 with placebo at week 104. For most people that is unremarkable, but if you have a tachyarrhythmia history or take rate-controlling therapy, raise it specifically with your cardiologist.

What should I tell my care team before a cardiac procedure?

That you are taking a GLP-1 receptor agonist. Both labels carry a warning about pulmonary aspiration during general anesthesia or deep sedation in patients receiving these medications, and instruct patients to inform healthcare providers of any planned surgeries or procedures. That includes cardiac catheterisation, cardioversion and endoscopy under sedation.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.